The initial results of the phase III clinical trial for RTS, S—currently the leading malaria
vaccine candidate—were recently announced, 1 amid international media coverage …

A phase III trial showed that the RTS, S vaccine, which acts against Plasmodium falciparum,
had an efficacy of around 30%. 1 The vaccine, which is most effective in children aged …

The World Health Organization has recommended widespread use of the RTS, S malaria
vaccine among children in sub-Saharan Africa and other areas with moderate to high …

The efficacy of the vaccine RTS, S/AS01 in infants aged 6-12 weeks against clinical and
severe malaria was 31% and 37%, respectively, found the study, published in the New …

RTS, S is thought to reduce the risk of infection from each exposure, rather than conferring"
all or nothing" protection on a proportion of recipients. 5 By this hypothesis, everyone …

The study included 6537 infants aged 6-12 weeks and 8922 children aged 5-17 months who
were enrolled at 11 centres in seven countries across sub-Saharan Africa. They were …

A candidate vaccine against malaria has been shown to almost halve the number of malaria
cases in young children but only to reduce cases by a quarter in infants. The effectiveness of …

Pedro Alonso, head of the Centre for International Health at the University of Barcelona,
Spain, and principal investigator of the vaccine trial, told a press conference earlier this …

Throughout the covid-19 pandemic, global health scientists and professionals worried not
only about this new and emerging viral infection but also about a potential diversion of …

“This second vaccine holds real potential to close the huge demand-and-supply gap,” said
WHO's regional director for Africa, Matshidiso Moeti.“Delivered to scale and rolled out …